| 6:45 a.m. |
Registration
|
| 7:30 a.m. |
Introduction by Moderators
|
| 7:35 a.m. |
2024 Harry Hirsch Leiter Award Recipient:
Infectious Etiologies of Conjunctival Tumors
Michael Antonietti, MD
|
| 7:42 a.m. |
1. Herpes vs OSSN: Infection vs Neoplasia
Despoina Theotoka |
| 7:49 a.m. |
2. Chemo-Immunotherapy Resistant Ocular Surface Squamous Neoplasia Managed with I-125 Brachytherapy
Pragat J. Muthu |
| 7:56 a.m. |
3. Ocular Exposure to a Murine Coronavirus Induces a Subclinical and Protective Immune Response in Mice
Jana Livingston |
| 8:03 a.m. |
4. Dysautonomia and Ocular Symptoms in Long-COVID Patients
Sakina Qazi |
| 8:10 a.m. |
5. Patients With Neurotrophic Keratopathy with Autoimmune Markers Have Worse Quality of Life Compared to Autoimmune Negative Neurotrophic Keratopathy Patients
Ana Balbuena-Pareja, MSc |
| 8:17 a.m. |
6. Exploring the Relationship Between Serum Autoantibodies and Longitudinal Changes in Dry Eye Disease
Shyamal Raolji |
| 8:24 a.m. |
7. Localizing Retinal Vessel Density Changes Associated with the Presence of Activated Dendritic Cells Using Optical Coherence Tomography Angiography
Alex Hattenhauer
|
| 8:31 a.m. |
8. Descemet's Membrane Anterior Keratoplasty (DMAK) Outcomes in Limbal Stem Cell Deficiency Assessed with Anterior Segment Optical Coherence Tomography-A Case Series
Neslihan Dilruba Koseoglu
|
| 8:38 a.m. |
9. Therapeutic Penetrating Keratoplasties in the Last 3 Years: A Subgroup Analysis for a Pilot Corneal Ulcer Clinic
Nicholas Joseph DeLuca
|
| 8:45 a.m. |
10. Real‑World Deployment of an AI Model for Potassium Hydroxide Smear Interpretation Reveals Critical Implementation Barriers
Jad F. Assaf, MD
|
| 8:52 a.m. |
11. Characterization of Endosymbiotic Microbiota, Mycotoxigenic Potential, and Metabolic Profiles of Fusarium Keratitis Isolates: Correlation with Clinical Outcomes
Salomon Merikansky, MD
|
| 8:59 a.m. |
12. Clinical Outcomes and in vitro Susceptibility Analysis of Fungal Keratitis Treated with Adjunct Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT) at the Federal University of Sao Paulo (UNIFESP)
Aileen Miwa Tabuse |
| 9:06 a.m. |
13. Photochemical Interactions Between Rose Bengal Photodynamic Therapy and Topical Antifungals Against Filamentous Fungal Keratitis Isolates
Brandon Chou |
| 9:13 a.m. |
14. Strain-Specific Impact of Melanin Pathway Inhibition on RB-PDAT Efficacy in Aspergillus Keratitis Isolates
Heather Durkee, PhD
|
| 9:20 a.m. |
BREAK and Poster Viewing
|
| 9:40 a.m. |
15. Activity of Photoactivated Rose Bengal Alone or Combined yo Standard Treatments in Trophozoites and Cysts of Acanthamoeba: In vitro Study
Talita Trevizani Rocchetti |
| 9:47 a.m. |
16. Standard, Repeat, and High Fluence Rose Bengal Photodynamic Antimicrobial Therapy in Clinical Acanthamoeba Keratitis Isolates: In vitro Cysticidal Effect
Juan Carlos Navia |
| 9:54 a.m |
17. Free-Living Amoebae in Contact Lens Cases-Biological By-Passes for Non-Amebic Keratitis?
Darlene Miller |
| 10:01 a.m. |
18. Clinical and Genomic Profile ofStaphylococcus aureus ST398 in Ocular Infections
Humza Qureshi
|
| 10:08 a.m. |
19. Dual Antibacterial Silver-Vancomycin Nanoparticles for the Treatment Experimental Bacterial Endophthalmitis
Ashok Kumar, PhD |
| 10:15 a.m. |
20. Over-the-Counter Artificial Tear Formulations Differentially Influence Microbial Growth of Staphylococcus aureus and Pseudomonas aeruginosa isolates
Felipe Echeverri Tribin
|
| 10:22 a.m. |
21. External Validation of a Multi-Regionally Trained Deep Learning Model for Trachomatous Inflammation – Follicular Detection
Hady Yazbeck
|
10:29 a.m. |
22. Investigating the Combination of Salinomycin and Ophthalmic Antibiotics in Treating Bacterial Keratitis and Preventing Corneal Scarring
Rebecca Li
|
| 10:36 a.m. |
23. Combating Multidrug-Resistant Pseudomonas Aeruginosa Keratitis: In vitro Synergy Between Cefiderocol and Moxifloxacin
Eric G. Romanowski, MSc |
10:43 a.m. |
24. Antimicrobial Efficacy, Ocular Surface Toxicity, and Cytokine Expression with Povidone-Iodine and Chlorhexidine
Anam Ahmed |
10:50 a.m. |
25. Vision-Related Quality of Life Outcomes in Patients Treated for Microbial Keratitis in the SCUT II Trial
Alejandro Arboleda |
| 10:57 a.m. |
OPEN QUESTIONS AND COMMENTS
|
|
BREAK and Poster Viewing
|
| 11:10 a.m. |
Introduction -- Thygeson Lecture
30th Thygeson Lecture: "Following the Mutations – Adventures in Bacterial Keratitis, Predators, and Virulence Factor Regulation"
Robert M. Q. Shanks, PhD
Director, Charles T. Campbell Ophthalmic Microbiology Laboratory
UPMC Mercy Vision Institute
Associate Professor of Ophthalmology
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania |
| 11:50 a.m. |
Questions, Closing Comments, Awards |
| 12:00 p.m. |
Adjourn |
| 12:15 p.m. |
Business Luncheon - Salon 11 (Level 2) |
|
- POSTER PRESENTATIONS -
26. Predictors of Visual Acuity Improvement in Fungal Keratitis: A Multivariate Analysis
Mamta Agarwal
27. Diagnostic Yield of Direct vs. Indirect Corneal Cultures in Infectious Keratitis
Kyle S. Chan
28. Referral Trends and Clinical Features of Neurotrophic Keratopathy Before and After Cenegermin Introduction
Onur Olcucu
29. Vancomycin is Poorly Active Against Staphylococcus Aureus Biofilms Formed by Endophthalmitis Isolates
Lucas Sejournet
29. Retrospective Review of Late-Onset Interstitial Keratitis in Post-Treatment Acanthamoeba Keratitiss
Grace Tu
|
